Background Bone is the most common site of metastatic disease associated with breast
cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel …

Background Bisphosphonates are specific inhibitors of osteoclastic activity and used in the
treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

Cervical cancer is one of the gravest threats to women's lives. It is estimated that over a
million women worldwide currently have cervical cancer. Most of these women have not …

Bone is one of the most common sites of metastasis from advanced solid tumors. Bone
metastasis is a leading cause of pain and increases the risk of skeletal-related events …

Purpose To update the recommendations on the role of bone-modifying agents in the
prevention and treatment of skeletal-related events (SREs) for patients with metastatic breast …

Purpose To investigate the efficacy and safety of zoledronic acid for the treatment of bone
metastases from breast cancer. Patients and Methods Women with bone metastases (N …

Abstract Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal
complications in patients, and have substantially decreased the prevalence of such events …

Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the importance of bone disease in the common solid tumors of adulthood. Describe the …

In postmenopausal women with hormone receptor-positive early-stage breast cancer, the
use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical …